ApconiX Press Category archive
ApconiX Newsletter January 2018
ApconiX Newsletter January 2018 Please click on the title to hear all about people, places and progress. Best regards Ruth, Mike and Richard
Professor Ruth Roberts Receives International Award
Professor Ruth Roberts – co-founder and director of nonclinical safety company, ApconiX based at Alderley Park, Cheshire – is the first non-US-based scientist to receive a prestigious international award for professionals specialising in drug and chemical safety. She is only the tenth person to receive the US-based Society of Toxicology (SOT) Founders Award, presented for “outstanding leadership in fostering the role [...]
ApconiX Achieves Five-Fold Turnover Boost
The business has just received the accolade of Start-Up of the Year at the 17th awards hosted by BioNow, the northern England bio-medical and life sciences membership organisation. The company’s early success is based on delivering expertise in safety toxicology and ion channel electrophysiology to a changing pharmaceutical sector, in which more companies are outsourcing [...]
Learning from Failure
Cardiovascular toxicity often hinders success – are companies picking the wrong compounds? Prolific novelist and academic CS Lewis once said, “Failures are finger posts on the road to achievement.” (Given pharma’s drug failure rate, the road ahead must truly be paved in gold.) When it comes to drug safety failure, toxicity – especially to the [...]
ApconiX Announce Their Alliance with PhysioStim.
The European Centre of Excellence for preclinical cardiovascular electrophysiology. The ApconiX team is pleased to announce their alliance with PhysioStim to create a new Centre of Excellence dedicated to cardiac safety studies. Both companies team up to offer a complete range of services in nonclinical cardiovascular electrophysiology. ApconiX, based at Alderley Park in the [...]
New Drug Discovery Alliance to Tackle High Rate of Failure
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development. This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right [...]
APTrans signs agreement with Evgen Pharma to support the development of the lead product, SFX-01.
In February, APTrans signed a service agreement with Evgen Pharma to provide support to their lead program, SFX-01. Evgen Pharma is a clinical stage drug development company with projects in breast cancer and subarachnoid haemorrhage. APTrans is a consortium of companies based at the BioHub at Alderley Park, formed by ApconiX, Aptus Clinical and Seda [...]
ApconiX New Year Message 2017!
As we get ready for a busy and exciting 2017, it’s a good time to reflect on ApconiX’s first full year in business and share some notable highlights. In 2016 we were joined by several additional preclinical experts including Dr Guy Healing, Dr Damian Deavall, Dr Jane Barber, Dr Mike O’Donovan and Dr Peter Ballard [...]
ApconiX Official Lab Opening!
ApconiX Official Lab Opening! It was a pleasure to welcome all our colleagues and collaborators to the official opening of the new ApconiX lab at Alderley Park March 1st 2016. Professor Graham Boulnois (Chair of the Drug Discovery Medicines Catapult) cut the red ribbon, surrounded by well-wishers and the [...]
ApconiX on the BBC News!
ApconiX was featured November 19th 2015 in a BBC News NorthWest item as one of the success stories of the Northern Power House (click here for video). BBC political correspondent Arif Ansari was interested to hear how we assembled a team of the best expert science professionals all of whom want to stay in the North [...]